NOVATO, Calif., Jan. 4, 2018/PRNewswire/ -- Mercaptor Discoveries, a preclinical-stage pharmaceutical company developing therapies based on proprietary, injury-activated, neuroprotective technology, received national coverage on Sports Illustrated's widely read website, si.com.
Written by acclaimed journalist Tom Taylor, who holds a PhD in Aeronautics and Astronautics, the article, entitled "Ex-Player Jim Kovach Helps Search for Medical Answers to Football's Concussion Problem," is part of the "Muscle and Medicine" series, which highlights cutting-edge technologies and innovations that improve performance and protect the health of NFL players. Sports Illustrated's print magazine reaches 17 million readers, and a large percentage of that audience consumes the iconic publication's award-winning content via its digital edition, si.com.
Jim Kovach, a Mercaptor Board member, was profiled. As a former San Francisco 49er, physician, attorney and entrepreneur, Kovach offered his unique perspective on the CTE epidemic. Not just an advocate of Mercaptor's work, he is also an enthusiastic potential patient.
If Mercaptor's unique efforts lead to the clinic, "I'll raise my hand and say 'Yes, me too,'" Kovach says.
Also quoted in the article was Sara Isbell, Mercaptor's CEO and co-founder, who explained "[Pathology after concussion] is like a ripple effect…we prevent those ripples from expanding."
The basis for the company's approach was a chance discovery. Insights from this bit of good fortune have the potential to change the trajectory of the NFL's concussion crisis with new first-line medical treatments for brain trauma. Mercaptor's tight-knit team learned a little in the process about looking beyond expectations toward what lay beneath. CSO Todd Zankel sums up the company's credo concisely, "Mistakes rescue science from the limitations of imagination."
Eager to avoid many of the inefficiencies and dogma entrenched the pharmaceutical industry, Mercaptor's researchers are striving to develop neuroprotective treatments that actually work. As journalist Tom Taylor's si.com article states, "Dubbed captons, these molecules promised to have few unwanted side effects, and to more easily pass through the blood-brain barrier—the semipermeable membrane that separates circulating blood from the extracellular fluid in the brain—than typical neuroprotective drugs."
About Mercaptor Discoveries Mercaptor Discoveries is a privately-held company that was founded in October 2016 by a team of scientists who discovered an injury-activated molecule with potential to mitigate brain damage when used prophylactically and treat many neurodegenerative diseases. They took a leap of faith and became a self-seeded enterprise with a clear goal: adapting their discovery to treat seizures, TBI, Alzheimer's disease, ALS, chronic traumatic encephalopathy, Parkinson's disease, stroke, and other debilitating conditions. Headquartered in Novato, California, Mercaptor Discoveries prioritizes science, promotes productivity and transparency, and values the purity of research.